Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone
作者单位：Prostate Cancer Targeted Therapy Group and Drug Development Unit, Royal Marsden NHS Foundation[1]Guy's and St. Thomas' NHS Foundation Trust, Great Maze Pond, London, United Kingdom[2]
换一批
换一批
![European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)](https://img.med.wanfangdata.com.cn/imgs/qkindeximg/N2007EPST0000700/N2007EPST0000700.jpg)
